TSHA Q1 2023 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M

Gross Profit

$4M86.6% margin

Operating Income

-$17M-351.9% margin

Net Income

-$18M-374.5% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+88.1%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$24M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$102M

Total Liabilities

$117M

Stockholders' Equity

-$15M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$0	—
Gross Profit	$4M	$0	—
Operating Income	-$17M	-$50M	+66.6%
Net Income	-$18M	-$50M	+65.0%